Cardiac rescue with enoximone in volume and catecholamine refractory septic shock

Pediatric Critical Care Medicine

Volumn 4, Issue 4, 2003, Pages 471-475

  Ringe, Hannelore I G ^a   Varnholt, Verena ^a   Gaedicke, Gerhard ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Enoximone; Meningococcal septicaemia; Phosphodiesterase inhibitor; Septic shock; Waterhouse Friderichsen syndrome

Indexed keywords

CARDIOTONIC AGENT; CATECHOLAMINE; ENOXIMONE; PLASMA SUBSTITUTE;

ARTICLE; CASE REPORT; CHILD; FEMALE; FORWARD HEART FAILURE; HUMAN; MALE; MENINGOCOCCOSIS; PRESCHOOL CHILD; SEPTIC SHOCK; TREATMENT FAILURE;

CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CATECHOLAMINES; CHILD; CHILD, PRESCHOOL; ENOXIMONE; FEMALE; HUMANS; MALE; MENINGOCOCCAL INFECTIONS; PLASMA SUBSTITUTES; SHOCK, SEPTIC; TREATMENT FAILURE;

EID: 2142678116     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/01.PCC.0000074275.61913.72     Document Type: Article

References (38)

1. Mok Q, Butt W: The outcome of children admitted to intensive care with meningococcal septicaemia. Intensive Care Med 1996; 22:259-263
2. Malley R, Huskins WC, Kuppermann N: Multivariable predictive models for adverse outcome of invasive meningococcal disease in children. J Pediatr 1996; 129:702-710
3. Focaccio A, Peters G, Movsesian M, et al: Mechanism of action of OPC-8490 in human ventricular myocardium. Circulation 1996; 93:817-825
4. Vandeplassche GM, Hermans CF, de Chaffoy de Courcelles DR, et al: Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs. J Cardiovasc Pharmacol 1992; 19:714-722
5. Zerkowski HR, Günnicker M, Freund U, et al: Low-output syndrome after heart surgery: Is a monotherapy with phosphodiesterase-III inhibitors feasible? A comparative study of amrinone and enoximone. Thorac Cardiovasc Surg 1992; 40:371-377
6. Shakar SF, Abraham WT, Gilbert EM, et al: Combined oral positive inotropic and betablocker therapy for treatment of class IV heart failure. J Am Coll Cardiol 1998; 31: 1336-1340
7. Saatvedt K, Lindberg H, Michelsen S, et al: Release of soluble tumor necrosis factor alpha receptors during and after cardiopulmonary bypass. Correlation with haemodynamic and clinical variables. Cytokine 1996; 8:944-948
8. Carmona RH, Tsao T, Dae M, et al: Myocardial dysfunction in septic shock. Arch Surg 1985; 120:30-35
9. Silverman H, Penaranda R, Orens JB, et al: Impaired beta adrenergic stimulation of cyclic adenosine monophosphate in human septic shock: Association with myocardial hyporesponsiveness to catecholamines. Crit Care Med 1993; 21:31-39
10. Kumar A, Kosuri R, Kandula P, et al: Effects of epinephrine and amrinone on contractility and cyclic adenosine monophosphate generation of tumor necrosis factor alpha-exposed cardiac myocytes. Crit Care Med 1999; 27: 286-292
11. Schmidt-Thews: Charakteristika des elementaren Erregungsablaufs. Verknüpfung von Erregung und Kontraktion Physiologie des Menschen. 28th Edition. New York, Springer, 2001, pp 474-484
12. Bethke T, Eschenhagen T, Klimkiewicz A, et al: Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts. Arzneimittelforschung 1992; 42:437-445
13. Gilbert EM, Hershberger RE, Wiechmann RJ, et al: Pharmacologic and hemodynamic effects of combined βagonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest 1995; 108:1524-1532
14. Cracowski JL, Stanke-Labesque F, Chavanon O, et al: Vasorelaxant actions of enoximone, dobutamine, and the combination on human arterial coronary bypass. J Cardiovasc Pharmocol 1999; 34:741-748
15. Grossmann M, Braune J, Ebert U, et al: Dilatory effects of phosphodiesterase inhibitors on human hand veins. Eur J Clin Pharmacol 1998; 54:35-39
16. Lowes BD, Simon MA, Tsvetkova TO, et al: Inotropes in the beta-blocker era. Clin Cardiol 2000; 23(Suppl III):11-16
17. Rapundalo ST, Solaro RJ, Kranias EG: Inotropic responses to isoproterenol and phosphodiesterase inhibitors in intact guinea pig hearts: Comparison of cyclic AMP levels and phosphorylation of sarcoplasmic reticulum and myofibrillar proteins. Circ Res 1989; 64: 104-111
18. Katz AM: Interplay between inotropic and lusitropic effects of cyclic adenosine monophosphate on the myocardial cell. Circulation 1990; 82(Suppl 2):7-11
19. Barton P, Garcia J, Kouatli A, et al: Haemodynamic effects of IV milrinone in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, interventional study. Chest 1996; 109:1302-1312
20. Polla B, Cappelli V, Canepari M, et al: Direct depressant effect of phosphodiesterase inhibitors on ATPase activity of cardiac myofibrils. Can J Physiol Pharmacol 1995; 73:661-664
21. Dorigo P, Maragno I: Interaction of amrinone with endogenous adenosine in guineapig atria. Br J Pharmacol 1986; 87:623-629
22. Earl CQ, Linden J, Weglicki WB: Inhibition of cyclic AMP-dependent protein kinase activity by the cardiotonic drugs amrinone and milrinone. Life Sci 1986; 39:1901-1908
23. Irazuzta JE, Pretzlaff RK, Rowin ME: Amrinone in pediatric refractory septic shock. Pediatr Crit Care Med 2001; 2:24-28
24. van der Zypp A, Rechtman M, Majewski H: The role of cyclic nucleotides and calcium in the relaxation produced by amrinone in rat aorta. Gen Pharmacol 2000; 34:245-253
25. Schlepper M, Thormann J, Kremer P, et al: Present use of inotropic drugs in heart failure. J Cardiovasc Pharmacol 1989;14(Suppl 1):9-19
26. Chatterjee K: Phosphodiesterase inhibitors: Alterations in systemic and coronary hemodynamics. Basic Res Cardiol 1989; 84(Suppl 1):213-224
27. Kauffman RF, Schenck KW, Utterback BG, et al: In vitro vascular relaxation by new inotropic agents: Relationship to phosphodiesterase inhibition and cyclic nucleotides. J Pharmacol Exp Ther 1987; 242:864-872
28. Vroom MB, Pfaffendorf M, van Wezel HB, et al: Effect of phosphodiesterase inhibitors on human arteries in vitro. Br J Anaesth 1996; 76:122-129
29. Boldt J, Kling D, Dietevich HA, et al: Drug interactions: The new phosphodiesterase inhibitor enoximone and the calcium channel blocker nifedipine in coronary surgery patients- Influence on hemodynamics and plasma concentrations. J Cardiovasc Pharmacol 1990; 15:37-43
30. Kern H, Schroder T, Kaulfuss M, et al: Enoximone in contrast to dobutamine improves hepatosplanchnic function in fluid-optimized septic shock patients. Crit Care Med 2001; 29:1519-1525
31. Hoang P, Fosse JP, Fournier JL, et al: Enoximone- noradrenaline combination in septic shock. Presse Med 1991; 20:1785
32. Uretsky BF, Lawless CE, Verbalis JG, et al: Combined therapy with dobutamine and amrinone in severe heart failure. Chest 1987; 92:657-662
33. Vincent JL, Madhoun T: Potentiation of the effects of enoximone by dobutamine infusion. Intensive Care Med 1989; 15:530-531
34. Lindsay CA, Barton P, Lawless S, et al: Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. J Pediatr 1998; 132:329-334
35. Booker PD, Gibbons S, Stewart JI, et al: Enoximone pharmacokinetics in infants. Br J Anaesth 2000; 85:205-210
36. Endres S, Sinha B, Fülle HJ: Amrinone suppresses the synthesis of tumor necrosis factor alpha in human mononuclear cells. Shock 1994; 5:377-380
37. Giroir BP, Beutler B: Effect of amrinone on tumor necrosis factor production in endotoxic shock. Circ Shock 1992; 36:200-207
38. Loick HM, Möllhoff T, Berends E, et al: Influence of enoximone on systemic and splanchnic oxygen utilisation and endotoxin release following cardiopulmonary bypass. Intensive Care Med 1997; 23:267-275